Heterozygous Deficiency of PHD2 Restores Tumor Oxygenation and Inhibits Metastasis via Endothelial Normalization
Author(s) -
Massimiliano Mazzone,
Daniela Dettori,
Rodrigo Leite de Oliveira,
Sonja Loges,
Thomas Schmidt,
Bart Jonckx,
Ya Tian,
Anthony A. Lanahan,
Patrick J. Pollard,
Carmen Ruiz de Almodóvar,
Frederik De Smet,
Stefan Vinckier,
Julián Aragonés,
Koen Debackere,
Aernout Luttun,
Sabine Wyns,
Bénédicte F. Jordan,
Alberto Pisacane,
Bernard Gallez,
Maria Grazia Lampugnani,
Elisabetta Dejana,
Michael Simons,
Peter J. Ratcliffe,
Patrick H. Maxwell,
Peter Carmeliet
Publication year - 2009
Publication title -
cell
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 26.304
H-Index - 776
eISSN - 1097-4172
pISSN - 0092-8674
DOI - 10.1016/j.cell.2009.01.020
Subject(s) - intravasation , biology , cancer research , downregulation and upregulation , microbiology and biotechnology , hypoxia (environmental) , metastasis , angiogenesis , oxygen , cancer , biochemistry , chemistry , genetics , organic chemistry , gene
A key function of blood vessels, to supply oxygen, is impaired in tumors because of abnormalities in their endothelial lining. PHD proteins serve as oxygen sensors and may regulate oxygen delivery. We therefore studied the role of endothelial PHD2 in vessel shaping by implanting tumors in PHD2(+/-) mice. Haplodeficiency of PHD2 did not affect tumor vessel density or lumen size, but normalized the endothelial lining and vessel maturation. This resulted in improved tumor perfusion and oxygenation and inhibited tumor cell invasion, intravasation, and metastasis. Haplodeficiency of PHD2 redirected the specification of endothelial tip cells to a more quiescent cell type, lacking filopodia and arrayed in a phalanx formation. This transition relied on HIF-driven upregulation of (soluble) VEGFR-1 and VE-cadherin. Thus, decreased activity of an oxygen sensor in hypoxic conditions prompts endothelial cells to readjust their shape and phenotype to restore oxygen supply. Inhibition of PHD2 may offer alternative therapeutic opportunities for anticancer therapy.
Accelerating Research
Robert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom
Address
John Eccles HouseRobert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom